ALK-Abello A/S (CPH: ALKB), a producer of pharmaceuticals for
allergy vaccination, on Wednesday reported a net loss of DKK1.0m, or DKK0.00 per diluted share, for the second quarter of 2017.
Alk-Abello produces pharmaceuticals for
allergy vaccination. The company is an international group with subsidiaries and associated companies worldwide.
Ball et al., "Nonanaphylactic synthetic peptides derived from B cell epitopes of the major grass pollen allergen, Phl p 1, for
allergy vaccination," Federation of American Societies for Experimental Biology Journal, vol.